NLS Pharmaceutics and Kadimastem merge to form NewcelX
NLS Pharmaceutics and Kadimastem have merged to create NewcelX, a Swiss biopharmaceutical company focused on neurodegenerative and metabolic diseases. The merger involved raising approximately $9 million through equity financing and a $25 million Equity Line of Credit. NewcelX plans to initiate a Phase 2a clinical study in ALS and expand its therapeutic pipeline over the next year.
NLS Pharmaceutics Ltd. and Kadimastem Ltd. have completed a merger to form NewcelX Ltd., a Swiss clinical-stage biopharmaceutical company. The newly combined company brings together Kadimastem’s advanced cell-therapy platforms with NLS’s expertise in neuroscience and small-molecule drug development, aiming to create innovative treatments for neurodegenerative and metabolic diseases. In connection with the merger, the companies raised approximately $9 million through equity financing and warrant exercises, with additional financial support from a $25 million Equity Line of Credit facility. NewcelX has outlined plans for multiple clinical milestones over the next year, including a Phase 2a clinical study in ALS and expansion of its therapeutic pipeline. The update was disclosed by NewcelX Ltd. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN14973) on November 04, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
